Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009)

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 2, 2011, Pages 223-227

  Sader, Helio S ^a,b   Farrell, David J ^a   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ceftazidime resistance; ESBL; Imipenem resistance; Nosocomial infections

Indexed keywords

AMIKACIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; TIGECYCLINE;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENCY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HEALTH CARE FACILITY; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UNITED STATES;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; UNITED STATES;

EID: 78651458382     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.020     Document Type: Article

References (13)

1. Castanheira M., Sader H.S., Deshpande L.M., Fritsche T.R., Jones R.N. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-betβ-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2008, 52:570-573.
2. Castanheira M., Sader H.S., Jones R.N. Antimicrobial susceptibility patterns of KPC-producing or CTX-M-producing Enterobacteriaceae. Microb. Drug Resist. 2010, 16:61-65.
3. Clinical and Laboratory Standards Institute M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2009, CLSI, Wayne, PA. 8th ed.
4. Clinical and Laboratory Standards Institute M100-S20-U. Performance standards for antimicrobial susceptibility testing: 20th informational supplement (June 2010 Update) 2010, CLSI, Wayne, PA.
5. EUCAST Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, April 2010 Available at:, Accessed June 10, 2010. http://www.eucast.org/clinical_breakpoints/.
6. Fishbain J., Peleg A.Y. Treatment of Acinetobacter infections. Clin. Infect. Dis. 2010, 51:79-84.
7. Hirsch E.B., Tam V.H. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 2010, 65:1119-1125.
8. The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 2010, 15:1081-1083. Infectious Diseases Society of America.
9. Livermore D.M. Tigecycline: what is it, and where should it be used?. J. Antimicrob. Chemother. 2005, 56:611-614.
10. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 2008, 46:1254-1263.
11. Perez F., Endimiani A., Ray A.J., Decker B.K., Wallace C.J., Hujer K.M., Ecker D.J., Adams M.D., Toltzis P., Dul M.J., Windau A., Bajaksouzian S., Jacobs M.R., Salata R.A., Bonomo R.A. Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J. Antimicrob. Chemother. 2010, 65:1807-1818.
12. Stein G.E., Craig W.A. Tigecycline: a critical analysis. Clin. Infect. Dis. 2006, 43:518-524.
13. Tygacil Package Insert Wyeth Pharmaceuticals, Philadelphia, PA 2010, Available at: www.tygacil.com. Accessed October, 2010.